Discover more near‑term opportunities with better event intelligence.
Fundz combines its own real-time funding and M&A intelligence with executive moves, hiring shifts and other company changes, weighs each signal against your ideal customer profile, and delivers a ranked daily shortlist with the context and decision maker to contact. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Acquiring Company
Genmab
Acquired Company
Merus N.V
Denmark
UtrechtBiotechnologyHealth CareGeneticsTherapeuticsBiotechnologyHealth CareTherapeuticsDescription
Genmab has completed the acquisition of Merus N.V. for $97.00 per share, making it a wholly owned subsidiary. The tender offer closed on December 12, 2025, and the back-end merger finalized on December 29, 2025. Genmab plans to integrate Merus' assets into its oncology portfolio and advance ongoing clinical trials. The transaction significantly enhances Genmab's capabilities in oncology therapeutic development.
Fundz sees it the moment Genmab makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Merus N.V?
Merus N.V was acquired by Genmab, based in Denmark. The deal was reported on September 30, 2026. Genmab is a biotechnology company focused on the creation and development of differentiated antibody therapeutics for the treatment of cancer. Genmab is privately held and operates in Biotechnology.
When did Genmab acquire Merus N.V?
Genmab's acquisition of Merus N.V was reported on September 30, 2026. Genmab has completed the acquisition of Merus N.V. for $97.00 per share, making it a wholly owned subsidiary. The tender offer closed on December 12, 2025, and the back-end merger finalized on December 29, 2025. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Merus N.V do?
Merus N.V. is a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics). It is privately held, operating in Biotechnology, and is based in Utrecht.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.